

# THE NEW POSTER CHILD OF MENTAL HEALTH: THE GUT-BRAIN AXIS

Antonis Chatzipanagiotou
Deree - The American College of Greece | PS4751A1 - Adult Psychopathology
Supervisor: Dr. Fotini-Sonia Apergi

**The gut-brain axis has reemerged as a critical player in mental health, linking microbiota to psychiatric and neurological disorders. This poster summarizes the mechanisms, psychiatric implications, and therapeutic potential of targeting the microbiome through diet, psychobiotics, and fecal microbiota transplantation. It also outlines limitations and future directions for personalized, regulated applications.**

## HISTORICAL & CONCEPTUAL INTRODUCTION

Ancient Greek, Chinese, and Indian medicine emphasized digestion's effect on emotion. Descartes and Brillat-Savarin highlighted the gut's symbolic and physical influence on mental states. Only recently, with the molecular study of dyspepsia and Metchnikoff's probiotic research, has science begun validating these intuitions. The term "psychobiotic" now refers to probiotics with mental health effects via the gut-brain axis.

## MECHANISM – THE GUT-BRAIN AXIS

Tripartite System: Vagus, Immune, and Hormonal Pathways

- Vagus nerve: 80% afferent; regulates mood, stress, and inflammation.
- Immune response: Dysbiosis triggers cytokine storms, elevating psychiatric risk.
- Hormonal route: Gut hormones modulate the HPA axis and neurotransmitter function.

✳ Key Insight: Vagotomy negates psychobiotic effects, proving gut-to-brain signaling.

## NEUROTRANSMITTERS FROM THE GUT

- Serotonin (90–95%) – mood, appetite
- GABA – inhibition, calm
- Dopamine – cognition, movement
- Norepinephrine – stress response
- Acetylcholine – gut motility
- Histamine & Melatonin – immune modulation & sleep

## PSYCHIATRIC DISORDERS AFFECTED

Depression: Serotonin/GABA reduction, cytokine-induced inflammation, HPA axis hyperactivation

Anxiety/PTSD: Loss of microbial diversity, HPA loop dysfunction

Autism (ASD): SCFA imbalances, permeability, systemic inflammation

Neurodegeneration (PD/AD): Preliminary links to amyloid plaques, α-synuclein, SCFAs



## INTERVENTIONS

1. Dietary Modifications
   - Mediterranean diet reduces depressive symptoms (SMILES trial)
   - High-fiber + fermented foods boost SCFA production
2. Psychobiotics
   - Meta-analysis: Modest mood/stress/sleep improvement
   - Issues: Strain variation, dosage inconsistency
3. Fecal Microbiota Transplant (FMT)
   - Promising results, but ethical and safety concerns remain
   - Rodent studies show depression transfer via microbiota

## CONTROVERSIES & CHALLENGES

- Human studies are mostly correlational
- Microbiome is highly individualized
- Confounders: antibiotics, circadian rhythm, diet, genetics

Unregulated Market Risks

- "Microbiome cures" often lack scientific rigor
- Need for FDA/EMA oversight

## FUTURE DIRECTIONS

- Multi-omic research: Understand genes + microbial function
- Epigenetics & AI-based gut profiling
- Personalized psychobiotics
- Global regulation & ethical oversight


- Dinan, T. G., & Cryan, J. F. (2017). The microbiome–gut–brain axis in health and disease. Gastroenterology Clinics, 46(1), 77–89.
- Foster, J. A., & Neufeld, K. A. M. (2013). Gut–brain axis: How the microbiome influences anxiety and depression. Trends in Neurosciences, 36(5), 305–312.
- Jacka, F. N., et al. (2017). A randomized controlled trial of dietary improvement for adults with major depression (SMILES trial). BMC Medicine, 15(1), 23.
- Kazemi, A., et al. (2019). Lactobacillus supplementation in mental health. J. Am. Coll. Nutr., 38(7), 633–640.
- Bravo, J. A., et al. (2011). Lactobacillus regulates GABA and behavior via the vagus nerve. PNAS, 108(38), 16050–16055.